Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma
October 07, 2015 at 08:00 AM EDT
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) ...
